Analysis of genetic damage and gene polymorphism in hepatocellular carcinoma (HCC) patients in a South Indian population

Digestive Diseases and Sciences

Volumn 58, Issue 3, 2013, Pages 759-767

  Mohana Devi, Subramaniam ^a   Balachandar, Vellingiri ^a   Arun, Meyyazhagan ^a   Suresh Kumar, Shanmugam ^a   Balamurali Krishnan, Balasubramanian ^a   Sasikala, Keshavarao ^a  

^a BHARATHIAR UNIVERSITY   (India)

Author keywords

Chromosomal alterations; Genotypic analysis; Hepatocellular carcinoma; Micronucleus; p53; XRCC1

Indexed keywords

ALPHA FETOPROTEIN; PROTEIN P53; XRCC1 PROTEIN;

ADULT; ARTICLE; BLOOD SAMPLING; CANCER SUSCEPTIBILITY; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; INDIAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICRONUCLEUS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADULT; CARCINOMA, HEPATOCELLULAR; DNA DAMAGE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDIA; LIVER NEOPLASMS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC;

EID: 84876675276     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2409-8     Document Type: Article

References (74)

1. Colombo M. Natural history of hepatocellular carcinoma. Cancer Imaging. 2005;5:85-88.
2. Motola Kuba D, Zamora Valdes D, Uribe M, et al. Hepatocellular carcinoma. An overview. Ann Hepatol. 2006;5:16-24.
3. Villa VD, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist. 2007;12:132-1331.
4. Bu X, Jia F, Wang W, et al. Coupled down-regulation of mTOR and telomerase activity during fluorouracil-induced apoptosis of hepatocarcinoma cells. Bio Med Central Cancer. 2007;7:208-215.
5. Chakraborty T, Bhuniya D, Chatterjee M, et al. Acanthus ilicifolius plant extract prevents DNA alterations in a transplantable Ehrlich ascites carcinoma-bearing murine model. World J Gastroenterol. 2007;13:6538-6548.
6. Penn State Milton S. Hershey Medical Center College of Medicine/Malignant Hepatoma. Available at: http://www.hmc.psu.edu/healthinfo/m/malignanthepatoma. htm. Accessed January 15, 2008.
7. Wong R, Corley DA. Racial and ethnic variations in hepatocellular carcinoma incidence within the United States. Am J Med. 2008;121:525-531.
8. Cha C, Fong Y, Jarnagin WR, et al. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg. 2003;197:753-758.
9. Oka H, Tamori A, Kuroki T, et al. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology. 1994;19:61-66.
10. Zheng SS, Xu X, Liang TB, et al. Liver transplantation for hepatocellular carcinoma: prognostic analysis of 89 cases. Zhonghua Wai Ke Za Zhi. 2005;43:450-454.
11. Xu X, Ke QH, Shao Z-X, et al. The value of serum a-fetoprotein in predicting tumor recurrence after liver transplantation for hepatocellular carcinoma. Dig Dis Sci. 2009;54:385-388.
12. Albertini RJ, Anderson D, Douglas GR, et al. IPCS guidelines for the monitoring of genotoxic effects of carcinogens in humans. Mutat Res. 2000;463:111-172.
13. Norppa H. Cytogenetic biomarkers. In: Mechanistic Considerations in the Molecular Epidemiology of Cancer. Lyon: IARC Science Publication; 2004:157.
14. Hagmar LS, Bonassi U, Strömberg A, et al. Chromosomal aberrations in lymphocytes predict human cancer: a report from the European Study Group on Cytogenetic Biomarkers and Health (ESCH). Cancer Res. 1998;58:4117-4121.
15. Bonassi S, Hagmar L, Strömberg U, et al. European Study Group on cytogenetic biomarkers and health. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens. Cancer Res. 2000;60:1619-1625.
16. Bonassi S, Znaor A, Ceppi C, et al. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis. 2007;28:331-338.
17. Grisham JW. Molecular genetic alterations in primary hepatocellular neoplasms: hepatocellular adenoma, hepatocellular carcinoma, and hepatoblastoma. In: Coleman WB, Tsongalis GJ, eds. The Molecular Basis of Human Cancer. Totowa: Humana Press Inc.; 2002:269-346.
18. Thorgeirsson SS, Grisham JW. Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet. 2002;31:339-346.
19. Midorikawa Y, Yamamoto S, Ishikawa S, et al. Molecular karyotyping of human hepatocellular carcinoma using single-nucleotide polymorphism arrays. Oncogene. 2006;25:5581-5590.
20. Balachandar V, Mohana Devi S, Lakshman Kumar B, et al. Cytogenetic analysis of benign prostate hyperplasia (BPH) and prostate cancer (PC) patients from Tamil Nadu, South India. Sci Res Essay (Academic Journal Publication). 2008;3:212-214.
21. Mohana Devi S, Balachandar V, Vel Murugan P, et al. Identification of chromosomal aberrations by using trypsin G- banding in hepatocellular carcinoma patients (HCC) in Tamilnadu, India. Trop Life Sci Res. 2010;21:33-49.
22. Wong N, Lai P, Pang E, et al. Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin Cancer Res. 2000;6:4000-4009.
23. Lu XG, Magrane C, Yin DN, et al. Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol Cell Biol. 2001;21:6017-6030.
24. Sheen IS, Jeng KS, Wu JY, et al. Is p53 gene mutation an indicator of the biological behaviors of recurrence of hepatocellular carcinoma? World J Gastroenterol. 2003;9:1202-1207.
25. Staib F, Hussain SP, Hofseth LJ, et al. TP53 and liver carcinogenesis. Hum Mutat. 2003;21:201-216.
26. Thompson LH, West MG. XRCC1 keeps DNA from getting stranded. Mutat Res. 2000;459:1-18.
27. Duell EJ, Wiencke JK, Cheng TJ, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis Lond. 2000;21:965-971.
28. Liu F, Li B, Wei Y, Yan L, et al. XRCC1 genetic polymorphism Arg399Gln and hepatocellular carcinoma risk: a meta-analysis. Liver Int. 2011;6:802-809.
29. Yu J, Zhang HY, Ma ZZ, et al. Methylation profiling of twenty four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res. 2003;13:319-333.
30. Whitehouse CJ, Taylor RM, Thistlethwaite A. XRCC1 stimulates human polynucleotide kinase activity at damaged DNA termini and accelerates DNA single-strand break repair. Cell. 2001;104:107-117.
31. Moorhead PS, Novell WJ, Mellman DM, et al. Chromosome preparations of leukocytes cultured from peripheral blood. Exp Cell Res. 1960;20:613-616.
32. Martin Bland J, Douglas G. Altman Statistics Notes: the odds ratio. BMJ. 2000;320:1468.
33. Frankish H. 15 million new cancer cases per year by 2020, says WHO. Lancet. 2003;361:1278.
34. Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27:1485-1491.
35. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
36. Jia HL, Ye QH, Qin LX. Gene expression profiling reveals potential biomarkers of human hepatocellular carcinoma. Clin Cancer Res. 2007;13:1133.
37. Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353:1253-1257.
38. Um SH, Mulhall C, Alisa A. a-Fetoprotein impairs APC function and induces their apoptosis. J Immunol. 2004;173:1772-1778.
39. Tilghman SM. The structure and regulation of the a-fetoprotein and albumin genes. Oxf Surv Eukaryot Genes. 1985;2:160-206.
40. Yao DF, Dong ZZ, Yao M. Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6:241-247.
41. Otsuru A, Nagataki S, Koji T, et al. Analysis of alpha-fetoprotein gene expression in hepatocellular carcinoma and liver cirrhosis by in situ hybridization. Cancer. 1988;62:1105-1112.
42. Taketa K. α-fetoprotein: reevaluation in hepatology. Hepatology. 1990;12:1420-1432.
43. Mizejewski GJ. Alpha-fetoprotein structure and function: relevance to isoforms, epitomes, and conformational variants. Exp Biol Med. 2001;226:377-408.
44. Lamerz R, Hayes P, Hoffmann RT. National Academy of Clinical Biochemistry (NACB). Guidelines for the use of tumor markers in primary liver cancer. Accessed Aug 2007. Available at URL address: http://www.nacb.org/Impg/tumor/ chp3d-liver.pdf; 2005.
45. Piao Z, Park C, Park JH, Kim H. Allelotype analysis of hepatocellular carcinoma. Int J Cancer. 1998;75:29-33.
46. Guan XY, Fang Y, Sham JS, et al. Recurrent chromosome alterations in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer. 2000;29:110-116.
47. Chang J, Kim NG, Piao Z, et al. Assessment of chromosomal losses and gains in hepatocellular carcinoma. Cancer Lett. 2002;182:193-202.
48. Jou YS, Lee CS, Chang YH. Clustering of minimal deleted regions reveals distinct genetic pathways of human hepatocellular carcinoma. Cancer Res. 2004;64:3030-3036.
49. Wong N, Lai P, Pang E. Hepatology. 2000;32:1060-1068.
50. Niketeghad F, Decker HJ, Caselmann WH, et al. Frequent genomic imbalances suggest commonly altered tumour genes in human hepatocarcinogenesis. Br J Cancer. 2001;85:697-704.
51. Yeh SH, Chen PJ, Shau WY, et al. Chromosomal allelic imbalance evolving from liver cirrhosis to hepatocellular carcinoma. Gastroenterology. 2001;121:699-709.
52. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology. 2001;120:1763-1773.
53. Patil MA, Gutgemann I, Zhang J, et al. Array-based comparative genomic hybridization reveals recurrent chromosomal aberrations and JAB1 as a potential target for 8q gain in hepatocellular carcinoma. Carcinogenesis. 2005;26:2050-2057.
54. Sheu JC. Molecular mechanism of hepatocarcinogenesis. J Gastroenterol Hepatol. 1997;12:S309-S313.
55. Norppa H, Luomahaara S, Heikanen H, et al. Micronucleus assay in lymphocytes as a tool to biomonitor human exposure to aneuploidogens and clastogens. Environ Health Perspect. 1993;101:139-143.
56. Fenech M. Cytokinesis-block micronucleus assay. Nature Protocols. 2007;2:1084-1104.
57. de Almeida TMB, Leitao RC, et al. Carrilhod, Shigueko Sonoharae, Detection of micronuclei formation and nuclear anomalies in regenerative nodules of human cirrhotic livers and relationship to hepatocellular carcinoma. Cancer Genet Cytogenet. 2004;150:16-21.
58. Bonassi S, Znaor A, Ceppi M, et al. An increased micronucleus frequency in peripheral blood lymphocytes predicts the risk of cancer in humans. Carcinogenesis. 2007;28:625-631.
59. Fenech M, Denham J, Francis W, Morely A. Micronuclei in cytokinesis blocked lymphocytes of cancer patients following fractionated partial-body radiotherapy. Int J Radiat Biol. 1990;57:373-383.
60. Gantenberg HW, Wuttke K, Streffer C, Muller WU. Micronuclei in human lymphocytes irradiated in vitro or in vivo. Radiat Res. 1991;128:276-281.
61. Livezey KW, Negorev D, Simon D. Increased chromosomal alterations and micronuclei formation in human hepatoma HepG2 cells transfected with the hepatitis B virus HBX gene. Mutat Res. 2002;505:63-74.
62. Umegaki K, Fenech M. Cytokinesis-block micronucleus assay in WIL2-NS cells: a sensitive system to detect chromosomal damage induced by reactive oxygen species and activated human neutrophils. Mutagenesis. 2000;15:261-269.
63. Countryman PI, Heddle JA. The production of micronuclei from chromosome aberrations in irradiated cultures of human lymphocytes. Mutat Res. 1976;41:321-332.
64. Cliet I, Fournier E, Melcion C, et al. In vivo micronucleus test using mouse hepatocytes. Mutat Res. 1989;216:321-326.
65. Van Goethem F, Ghahroudi MA, Castelain P, et al. Frequency and DNA content of micronuclei in rat parenchymal liver cells during experimental hepatocarcinogenesis. Carcinogenesis. 1993;14:2397-2406.
66. Fenech M, Holland N, Chang WP, et al. The Human MicroNucleus Project - an international collaborative study on the use of the micronucleus technique for measuring DNA damage in humans. Mutat Res. 1999;428:271-283.
67. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
68. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53gene in hepatocellular carcinoma from southern Africa. Nature. 1991;350:429-431.
69. Tudek B. Base excision repair modulation as a risk factor for human cancers. Mol Aspects Med. 2007;28:258-275.
70. Au WW. Heritable susceptibility factors for the development of cancer. J Radiat Res. 2006;47:13-17.
71. Cornetta T, Festa F, Testa A, Cozzi R. DNA damage repair and genetic polymorphisms: assessment of individual sensitivity and repair capacity. Int J Radiat Oncol Biol Phys. 2006;66:537-545.
72. Vettriselvi V, Vijayalakshmi K, Solomon PF. XRCC1 and XPD gene polymorphisms in a South Indian population. Asian Pac J Cancer. 2007;8:283-286.
73. Wang G, Zhao Y, Liu X, et al. Allelic loss and gain, but not genomic instability, as the major somatic mutation in primary hepatocellular carcinoma. Genes Chromosomes Cancer. 2001;31:221-227.
74. Okabe H, Ikai I, Matsuo K, et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology. 2000;31:1073-1079.